
Hikma Invests $267M in Ohio; Cingulate Faces Hurdles with ADHD Drug Approval
Hikma Pharmaceuticals plans to invest $267 million in Ohio manufacturing, boosting the local economy and potentially creating job opportunities. Meanwhile, Cingulate Therapeutics encounters challenges with the approval of their ADHD drug, highlighting the complexities of the pharma industry.









